The role of METTL16 RNA methyltransferase in gene regulation in prostate cancer

作者
Amber A. Kumari
出处
期刊:University of Nottingham - Nottingham ePrints [University of Nottingham]
链接
摘要

Prostate cancer (PCa) is one of the most commonly diagnosed cancers in men globally and is primarily driven by the androgen receptor (AR). Current therapeutic options for patients with metastatic disease include androgen deprivation therapy (ADT) such as enzalutamide. Despite an initial response to ADT, over half of patients receiving this treatment eventually progress to a treatment-resistant form of PCa, known as castration resistant PCa (CRPC). CRPC is currently incurable, although therapeutics are given to manage symptoms of the disease. N6-methyladenosine (m6A) is the most prevalent internal chemical modification in all eukaryotic cells and plays a role in a dynamic range of biological processes, including transcriptional and translational regulation, cell cycle progression and metabolism. Aberrant m6A has been associated with PCa. The addition of m6A is catalysed by “writers” such as METTL3, METTL14 complex and METTL16. The m6A methylation marks are removed by demethylases, also known as “erasers” (FTO and ALKBH5), and interpreted and processed by “readers” such as YTHDC and other YTH family members. While the METTL3:METTL14 RNA methyltransferase complex targets mRNA, the METTL16 methyltransferase has a more limited substrate preference for a select number of RNAs, including U6 snRNA, MAT2A RNA and MALAT1 lncRNA, which has also been implicated in PCa. Although METTL16 has been associated with several cancer types, its role appears to be context-dependent, and its clinical and functional significance in PCa remains poorly understood. The wealth of evidence supporting the clinical and mechanistic relevance of m6A in PCa progression and treatment resistance, supports the hypothesis that METTL16 plays an important role in pro-oncogenic signalling in PCa. To test this hypothesis, this study aimed to quantify METTL16 expression in non-malignant and primary PCa tissue patient specimens and investigate its association with clinical and pathological parameters. Additionally, the functional role of METTL16 in enzalutamide-sensitive and resistant cell lines was assessed by siRNA-mediated METTL16 Knockdown and analysis of differentially expressed genes and alternative splicing events were performed using RNA sequencing data. A positive correlation was observed between nuclear METTL16 and METTL3 expression in PCa specimens. Increased METTL16 nuclear expression was associated with more favourable disease outcomes, such as reduced extra prostatic extension and recurrence. In contrast, increased METTL16 cytoplasmic expression was associated with less favourable outcomes, including a higher Gleason score, perineural invasion and extra prostatic extension. SiRNA-mediated METTL16 depletion was achieved at the protein and mRNA level in both enzalutamide-sensitive and resistant cell lines (C4-2 and C4-2enzR, respectively). METTL3 mRNA levels were significantly downregulated following METT16 depletion in C4-2enzR but not C4-2, suggesting a possible mechanistic link between the two methyltransferases in an enzalutamide-resistant environment. Although C4-2 RNA-seq data showed no statistically significant enriched pathways, C4- 2enzR had substantially more. Oxidative phosphorylation was one of the significantly enriched downregulated pathways, while ribosome and spliceosome were among the significantly upregulated pathways. Splicing analysis also displayed more significant enrichments in splicing events in C4-2enzR, compared to C4-2. KEGG pathways with significantly enriched splicing events in C4-2enzR included mTOR, Wnt signalling and DNA repair mechanisms. Together, this study suggests that METTL16 is associated with positive or negative prognostic indicators, depending on cellular localisation, highlighting a complex, context specific role that METTL16 plays in PCa. Additionally, this study highlights a more prominent role of METTL16 in enzalutamide-resistant PCa cells compared to enzalutamide-sensitive cells. These findings also demonstrate a previously unknown potential mechanistic link between METTL16 and METTL3, which was not observed in the enzalutamide-sensitive cells. Collectively, these findings contribute to a deeper understanding of the mechanisms that drive ADT resistance in prostate cancer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
忧郁的莫茗完成签到,获得积分10
刚刚
小橘完成签到,获得积分10
2秒前
李爱国的应助被科研不是科幻采纳,获得10
2秒前
2秒前
3秒前
enkidu发布了新的文献求助10
3秒前
也未可知完成签到 ,获得积分0
3秒前
3秒前
丹丹完成签到 ,获得积分10
3秒前
yian007发布了新的文献求助10
4秒前
香辣牛排发布了新的文献求助10
4秒前
4秒前
孔之如冬完成签到 ,获得积分10
4秒前
4秒前
5秒前
chan完成签到,获得积分10
5秒前
秋风的应助被郦稀采纳,获得10
5秒前
杨青黄发布了新的文献求助10
6秒前
7秒前
mhx1234567890完成签到,获得积分20
7秒前
cjr发布了新的文献求助10
7秒前
xiejie发布了新的文献求助10
7秒前
科烟生完成签到,获得积分10
7秒前
8秒前
所所的应助被果粒橙采纳,获得10
8秒前
8秒前
huang完成签到,获得积分10
9秒前
小羊发布了新的文献求助10
10秒前
Gilhog完成签到,获得积分10
10秒前
小蘑菇的应助被PhDL1采纳,获得10
10秒前
光亮绮山完成签到,获得积分10
10秒前
Nothing完成签到,获得积分10
11秒前
12秒前
12秒前
12秒前
12秒前
3475发布了新的文献求助10
13秒前
树枝完成签到 ,获得积分10
13秒前
cjr完成签到,获得积分10
14秒前
共享精神的应助被无糖可乐采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593